{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:16Z","timestamp":1777934716100,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Melanoma, though relatively rare, is the most aggressive form of skin cancer due to its high metastatic potential and mortality rate. Immunotherapy, such as pembrolizumab, has improved outcomes for patients. However, access to these therapies remains limited in low- and middle-income countries, including Brazil, where real-world evidence is scarce and population genetics may influence treatment response and adverse drug reactions (ADRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to analyze the effectiveness and safety of first-line treatment for advanced melanoma with pembrolizumab, with a focus on the kinetics of ADRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included patients from the Brazilian Public Health System, with a follow-up period of 1 year (CAAE: 95157018.9.0000.5274).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study analyzed 40 patients (57.5% male, median age 65.5 years). The most frequent primary site of melanoma was the lower limbs (47.5%), and the main histological types were acral (30%) and nodular melanoma (30%). ADRs were identified in 87.5% of the patients, with pruritus (40%) and vitiligo (37.5%) being the most common. Cutaneous reactions were observed in the early cycles and persisted until the end of treatment. The cohort exhibited a different ADR profile and fewer severe events (10.5%) compared to clinical trials. The median progression-free survival was 7.7 months, and the overall survival rate was 60%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pembrolizumab was effective and safe as a first-line treatment for advanced melanoma patients in a real-world Brazilian public health setting. Additionally, we characterized the kinetics of ADRs, offering practical insights for healthcare teams in managing these events throughout the treatment course.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251410864","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T18:26:18Z","timestamp":1770315978000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness, Safety, and Adverse Event Kinetics of Pembrolizumab in Advanced Melanoma within the Brazilian Public Health System"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-0445","authenticated-orcid":false,"given":"Hildeneide Rocha","family":"Lima","sequence":"first","affiliation":[{"name":"Instituto Nacional de C\u00e2ncer (INCA)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-8817","authenticated-orcid":false,"given":"Mahanna Vanzeler","family":"Vaz","sequence":"additional","affiliation":[{"name":"Instituto Nacional de C\u00e2ncer (INCA)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-1498","authenticated-orcid":false,"given":"Rebeka Carib\u00e9","family":"Badin","sequence":"additional","affiliation":[{"name":"Instituto Nacional de C\u00e2ncer (INCA)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-6949","authenticated-orcid":false,"given":"Rodrigo Saar","family":"da Costa","sequence":"additional","affiliation":[{"name":"Instituto Nacional de C\u00e2ncer (INCA)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-3745","authenticated-orcid":false,"given":"Liliane Rosa Alves","family":"Mana\u00e7as","sequence":"additional","affiliation":[{"name":"Instituto Nacional de C\u00e2ncer (INCA)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"63","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala K","year":"2021","unstructured":"Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of melanoma. Med Sci (Basel) 2021; 9: 63.","journal-title":"Med Sci (Basel)"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2019.09.005"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0160"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.32635\/2176-9745.RBC.2023v69n1.3700"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj138"},{"key":"e_1_3_3_7_2","first-page":"1","article-title":"Terapia-alvo versus dacarbazina no tratamento de primeira linha do melanoma avan\u00e7ado n\u00e3o cir\u00fargico e metast\u00e1tico: an\u00e1lise de impacto or\u00e7ament\u00e1rio na perspectiva do Sistema \u00danico de Sa\u00fade, 2018\u20132020","volume":"28","author":"Correa FM","year":"2019","unstructured":"Correa FM, Guerra RL, Fernandes RRA, et al. Terapia-alvo versus dacarbazina no tratamento de primeira linha do melanoma avan\u00e7ado n\u00e3o cir\u00fargico e metast\u00e1tico: an\u00e1lise de impacto or\u00e7ament\u00e1rio na perspectiva do Sistema \u00danico de Sa\u00fade, 2018\u20132020. Epidemiol Serv Saude 2019; 28: 1\u201312.","journal-title":"Epidemiol Serv Saude"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2020.111982"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2022.07.007"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4514"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.017"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac219"},{"key":"e_1_3_3_18_2","unstructured":"BRASIL Resolu\u00e7\u00e3o - RE No - 848 DE 1o \u2013 de abril de 2016. Di\u00e1rio Oficial da Rep\u00fablica Federativa do Brasil Poder Executivo Bras\u00edlia DF 04 abril 2016. https:\/\/pesquisa.in.gov.br\/imprensa\/jsp\/visualiza\/index.jsp?jornal=1010&pagina=29&data=04\/04\/2016. (Accessed 05 Dec 2023)."},{"key":"e_1_3_3_19_2","unstructured":"BRASIL Minist\u00e9rio da Sa\u00fade. O Minist\u00e9rio da Sa\u00fade incorpora imunoterapia para tratamento do melanoma 2020. https:\/\/www.gov.br\/conitec\/pt-br\/assuntos\/noticias\/2020\/agosto\/ministerio-da-saude-incorpora-imunoterapia-para-tratamento-do-melanoma (Accessed 18 Dec 2023)."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1590\/1413-81232022276.16282021"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_3_22_2","unstructured":"Common Terminology Criteria for Adverse Events. U.S. Department of Health and Human Services. version 5.0 2017."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_3_3_24_2","unstructured":"American Cancer Society. Survival Rates for Melanoma Skin Cancer. https:\/\/www.cancer.org\/cancer\/types\/melanoma-skin-cancer\/detection-diagnosis-staging\/survival-rates-for-melanoma-skin-cancer-by-stage.html (Accessed 20 Apr 2024)."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.013"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2022.06.001"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100947"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0018"},{"key":"e_1_3_3_29_2","unstructured":"Sociedade Brasileira de Oncologia Cl\u00ednica (SBOC). Guia Sociedade Brasileira de Oncologia Cl\u00ednica (SBOC)- Melanoma cut\u00e2neo. 2023."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.058"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.010"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071737"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413302"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0102-311X2009000800001"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34742"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0077"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13801"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1712473"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.6018"},{"key":"e_1_3_3_42_2","first-page":"90","article-title":"Acesso a oncol\u00f3gicos no Brasil: um estudo de monitoramento p\u00f3s recomenda\u00e7\u00e3o de incorpora\u00e7\u00e3o pela CONITEC no caso do Melanoma Metast\u00e1tico","volume":"1","author":"Fernandes RRA","year":"2023","unstructured":"Fernandes RRA, Zimmerman IR, Andrade KRC. Acesso a oncol\u00f3gicos no Brasil: um estudo de monitoramento p\u00f3s recomenda\u00e7\u00e3o de incorpora\u00e7\u00e3o pela CONITEC no caso do Melanoma Metast\u00e1tico. J Assist Farmac\u00eautica Farmacoeconomia 2023; 1: 90.","journal-title":"J Assist Farmac\u00eautica Farmacoeconomia"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251410864","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251410864","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251410864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:07Z","timestamp":1777689127000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251410864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":41,"alternative-id":["10.1177\/10781552251410864"],"URL":"https:\/\/doi.org\/10.1177\/10781552251410864","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"10781552251410864"}}